Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is between 18 years and 80 years of age.~2. Subject is diagnosed with Type I or Type II diabetes, and had defined as diabetic foot ulcers presence of wound for more than 4 weeks at the screening visit.~3. Ulcer located the foot, and ulcer size is between 1 cm\^2 and 25 cm\^2.~4. Ulcer extends into the dermis, subcutaneous tissue, tendon or joint capsule (Wagner grade 1 or 2).~5. Ulcer is free of necrotic debris.~6. Subjects had adequate circulation to ulcer as documented by one of the methods below:~   * Palpation of pulses around ulcer using Doppler exam~  * Ankle Brachial index (ABI) values ranging between 0.7 and 1.3, or~  * Transcutaneous Oxygen Pressure (TcPO2) \> 30 mmHg.~7. Subject is able to give written informed consent prior to study start and to comply with the study requirements.~Exclusion Criteria:~1. Ulcer is of non-diabetic pathophysiology.~2. The ulcer has increased or decreased in size by 30% or more during one week after the screening visit.~3. Subject is Human Immunodeficiency Virus (HIV) positive.~4. Subjects with severe hepatic deficiencies.~5. Subjects with a glycated hemoglobin A1c (HbA1c) level of \> 15%.~6. Subject who are allergic or have a hypersensitive reaction to bovine-derived proteins or fibrin glue.~7. Subjects requiring intravenous (IV) antibiotics to treat the index wound infection.~8. Subjects with severe renal deficiencies that is uncontrolled by dialysis~9. Subjects who are pregnant or breast-feeding.~10. Subjects who are unwilling to use an effective method of contraception during the study.~11. Current evidence of severe infection including pus drainage from the wound site.~12. Subjects who have a clinically relevant history of alcohol or drugs abuse.~13. Subject's blood sugar is \> 450 mg/dL at postprandial.~14. Subjects who are not able to understand the objective of this study or to comply with the study requirements.~15. Subjects who are considered to have a significant disease which can impact the study by the investigator.~16. Subjects who are considered not suitable for the study by the investigator.~17. Subjects who have a history of surgery for malignant tumor within the last five years (except carcinoma in situ).~18. Subjects who are currently or were enrolled in another clinical study within 60 days of screening.~19. Subjects who have undergone wound treatments with cell therapy, dermal substitutes, or other biological therapies within the last 30 days.~20. Subjects who are receiving oral or parenteral corticosteroids, immunosuppressive, or cytotoxic agents to unstable dosage.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ALLO-ASC-DFU (Type: EXPERIMENTAL): Allogeneic mesenchymal stem cells
- Standard therapy (Type: ACTIVE_COMPARATOR): Standard therapy for patients with diabetic foot ulcer

Based on this trial design, predict the completion outcome and termination type (if applicable).